Lower Costs on the Horizon for Life-Saving Insulin Products
Hope coming for over 1.3 million diabetic adults currently struggling with the cost of their insulin.
AscellaHealth
Potential New Therapies on the Horizon for Duchenne Muscular Dystrophy
Promising new treatment options for Duchenne Muscular Dystrophy (DMD).
End-to-End Solutions Optimize Specialty Product Access and Market Entry in the US, EU and UK, Enhance Outcomes for Rare Disease Patients
Recognizing Rare Disease Day on February 28, to help raise awareness of the 7,000+ rare diseases.
Leqembi™ Now Approved by FDA for the Treatment of Alzheimer’s Disease
A bi-weekly IV infusion approved through the FDA’s accelerated approval pathway
Hemgenix® is First Gene Therapy Approved by FDA as Treatment for Hemophilia B
On November 22, 2022, the FDA approved Hemgenix® (etranacogene dezaparvovec-drlb)
Adstiladrin Earns FDA-Approval as New Gene Therapy for Bladder Cancer
Providing healthcare professionals with an innovative treatment option for patients with high-risk non-muscle invasive bladder cancer.
Novel ALS Drug – Relyvrio – Approved by FDA
Newly approved treatment for patients suffering with amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease.
Precision Medicine and Pharmacogenomics
The value of "personalized medicine" as an innovative approach to disease prevention and treatment.
The Changing Biosimilar Landscape
Biologic medications bringing hope to patients suffering from a variety of medical conditions.
Breakthrough Type 1 Diabetes Onset Prevention Therapy on the Horizon
Studies show that new prevention therapy are near.
Update on Recent Breast Cancer Treatment Drug Enhertu New FDA Approval Expands Indications for Most Aggressive Form of HER2-positive Breast Cancer
New FDA Approval Expands Indications for Most Aggressive Form of HER2-positive Breast Cancer.
Digital Therapeutics Provide Consumers with Software-Based Product to Prevent, Manage or Treat Medical Disorders or Diseases
Benefits for Digital therapeutics (DTx).
Recent Breast Cancer Treatment Drug Enhertu Indicates Expanding Options for Most Aggressive Form of HER2-positive Breast Cancer
The FDA approved drug for adult patients with metastatic HER2-positive breast cancer.